



Final Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
6 - 8 April 2009
CCV/CICG, Geneva

Monday, 6 April 2009

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction		20mn
09:20	Report from IVB Director including status of implementation of recommendations Presentation: J.-M. Okwo-Bele, WHO, 20mn Discussion: 20mn	FOR INFORMATION	40mn
10:00	Priorities, major policy and implementation issues: reports from AFRO, EMRO and SEARO Presentation: D. Nshimirimana, WHO 20mn Discussion: 20mn	FOR INFORMATION & DISCUSSION	2hrs
10:40	Coffee/tea break	Break	30mn
11:10	Priorities, major policy and implementation issues: reports from AFRO, EMRO and SEARO (contd.) Presentation: N. Teleb, WHO 20mn Discussion: 20mn Presentation: L. Mendis, Chair of Regional ITAG, 20mn Discussion: 20mn		
12:30	Lunch	Break	1hr 30mn

14:00	Polio eradication Feasibility of completing polio eradication and next steps: findings of November 2008 meeting of the ACPE S. Cochi, Chair, ACPE, 20mn Discussion: 20mn Progress towards mobilizing sub-national political support and improving community engagement for polio eradication in Nigeria: evidence of impact M. Pate, Executive Director, National Primary Health Care Development Agency, 20mn Discussion: 30mn New inter-provincial and inter-ministerial Government initiatives on polio eradication in Pakistan: evidence of impact R. Jooma, Federal Director General Health, Ministry of Health, 20mn (via phone connection) Discussion: 30mn Update of the activities of the IPV Working Group: framework for post-eradication vaccination policy options, and timeline of major Working Group 'deliverables'. L. Miller Chair of WG and SAGE member, 20mn Discussion: 20mn	FOR DISCUSSION & POSSIBLE DECISION Risk management for polio eradication and long-term strategies for mitigating post eradication risks including options for IPV use. The session will include a report by Pakistan and Nigeria on progress in overcoming barriers to achieving high coverage during OPV vaccination campaigns, a report from ACPE, and a report of the IPV working group.	3hrs
15:30	Coffee/tea break	Break	30mn
16:00	Polio eradication (contd.)		
18:00	Cocktail		

Tuesday, 7 April 2009

08:30	H5N1 influenza vaccine H5N1 Influenza Vaccine Working Group report to SAGE: review of evidence PH. Lambert, Member of WG, 15mn H5N1 Influenza Vaccine Working Group report to SAGE:	FOR DISCUSSION AND DECISION -For discussion on the evidence gathered and analyzed, and which could support a recommendation on potential uses of H5N1 influenza vaccine in the inter-pandemic period.	1hr 30mn
-------	---	---	----------

	<p>recommendations to SAGE S. Chunsuttiwat, Chair of WG and SAGE member, 15mn</p> <p>Discussion: 1hr</p>	-For decision on those questions for which SAGE will consider that enough evidence is available	
10:00	<p>Reports from other Advisory Committees in Immunization - Global Advisory Committee on Vaccine Safety (GACVS) P. Smith, Chair of GACVS, 10mn</p> <p>Discussion: 15mn</p>	FOR INFORMATION	1hr 15mn
10:25	Coffee/tea break	Break	30mn
10:55	<p>Reports from other Advisory Committees in Immunization (contd.) - Technologies and Logistics Advisory Committee (TLAC) R. Eggers, WHO (B. Weniger, Chair of TLAC, unavailable) 10mn</p> <p>Discussion: 15mn</p> <p>- Quantitative Immunization and Vaccines Related Research Committee (QUIVER) - A. Hinman, Chair of QUIVER, 10mn</p> <p>Discussion: 15mn</p>	FOR INFORMATION	
11:45	<p>Report from the GAVI secretariat Presentation: GAVI Alliance, N. Schwalbe, GAVI Alliance, 20mn</p> <p>Discussion: 25mn</p>	FOR INFORMATION	45mn
12:30	Lunch	Break	1hr 30mn
14:00	<p>Hepatitis B vaccine</p> <p>Introduction: L. Xiaofeng, SAGE member and Chair WG, 5mn</p> <p>Evidence to support the use and timing of the hepatitis B birth dose for perinatal prevention of hepatitis B infection: J. Ward, member of WG, 20mn</p> <p>Discussion: 40mn</p> <p>Evidence to support the current policy of not requiring booster doses of hepatitis B: G. Peter, member of WG, 15mn</p>	<p>FOR DECISION -Review WHO recommendations with respect to:</p> <ol style="list-style-type: none"> 1. the use of a birth dose of hepatitis B vaccine Information provided for decision will include the scientific basis for the birth dose including timing and options; the role of HBIG; and prospects for policy. This session will also review some issues specific to monitoring the birth dose coverage. 2. Duration of protection Information provided will include the scientific basis for long-term protection 	2hrs 00mn

		of a primary series of hepatitis B vaccine. This session will review the continuation of a no booster dose policy and need for further monitoring of evidence from long-term cohorts. This will lead to updating of the WHO hepatitis B vaccine position paper.	
15:20	Coffee/tea break	Break	30mn
15:50	Hepatitis B vaccine (contd.) Discussion: 40mn		
16:30	Impact of policy recommendations: report of a Stakeholders' panel Panel's report, A. Hinman, Panel member, 15mn Discussion: 45mn	FOR DISCUSSION	1hr
17:30	End of meeting		

Wednesday, 8 April 2009

08:30	Measles Introduction H. Bashour, SAGE member and Chair WG, 15mn Conclusions from the 3rd Meeting of the SAGE Working Group on Measles and Draft Recommendations for introduction of a second dose of measles vaccine delivered through routine services - S. Cochi, member of the WG, 30mn Discussion: 45mn Assessing the feasibility of establishing a goal for global elimination of measles - A. Dabaghi, WHO, 30mn	FOR INFORMATION, DISCUSSION AND DECISION - For decision - Criteria for introduction of a routine second dose. - For information and discussion Feasibility and programme of work towards establishing a global measles elimination goal: Update on workplan.	2hrs 30mn
10:30	Coffee/tea break	Break	30mn
11:00	Measles (contd.) Discussion: 30mn	FOR INFORMATION, DISCUSSION AND DECISION	

11:30	Review of updated safety, immunogenicity and efficacy data of rotavirus vaccines Introduction of Rotavirus issues G. Peter, Brown University, 5mn Impact and effectiveness of routine rotavirus vaccination in the Americas U. Parashar, CDC, 10mn Clinical studies of rotavirus vaccines in Africa and Asia K. Neuzil, PATH, 25mn Proposed recommendations Z. Bhutta, SAGE member, 10mn Questions for clarification 10mn	FOR DISCUSSION AND DECISION Specific points for discussion will include: -Possibility to extrapolate vaccine efficacy data to populations in similar WHO mortality strata; - Possibility to issue a generic versus product specific recommendations; -Scheduling options (number of doses and extension of the upper age limit for last dose); Decision on update of recommendations on use of rotavirus vaccines. This will lead to updating of the WHO rotavirus vaccine position paper.	3hrs
12:30	Lunch break	Break	1hr 30mn
14:00	Review of updated safety, immunogenicity and efficacy data of rotavirus vaccines (contd.) Discussion: 2hrs		
16:00	Closing		30mn
16:30	End of meeting		